Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389877 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
A Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Beam Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
- 11
- Study locations
NCT06389877: Recruiting Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Beam Therapeutics.
NCT06389877 is a Phase 1 study of Alpha-1 Antitrypsin Deficiency that is actively recruiting participants, run by Beam Therapeutics. The registered enrollment target is 106 participants, below the 2,337-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (95% lower). The trial reports 11 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06389877, a Phase 1 study of Alpha-1 Antitrypsin Deficiency, is actively recruiting participants, sponsored by Beam Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).
Primary Outcome
Numbers and percentages of patients reporting a given AE
Conditions Studied
Interventions
- DRUG BEAM-302
Study Locations (11)
Other
- Clinical Study Center - Adelaide
- Clinical Study Center - Fitzroy
- Clinical Study Center - Dublin
- Clinical Study Center - Leiden
- Clinical Study Center - Auckland
- Clinical Study Center - Hamilton
- Clinical Study Center - London
- Clinical Study Center - Southampton
Alabama
- Clinical Study Center - Birmingham
Massachusetts
- Clinical Study Center - Boston
South Carolina
- Clinical Study Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2030-05 |
| Phase | Phase 1 |
What NCT06389877 shows while recruiting
NCT06389877 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 2,337-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which BEAM-302 is the first listed.
NCT06389877 lists 11 locations in 4 states (Other, Alabama, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06389877 about?
NCT06389877 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)". This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD...
What is the current status of trial NCT06389877?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2024-06-19. Estimated completion is 2030-05.
What conditions does trial NCT06389877 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT06389877?
The interventions under investigation include: BEAM-302 (DRUG).
Who is sponsoring clinical trial NCT06389877?
This trial is sponsored by Beam Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06389877 being conducted?
This trial has 11 study locations across Alabama, Massachusetts, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06389877's enrollment target sits among peer trials
106 11th of 24 higher than 14 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
-
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of VX-668
COMPLETED · Phase 1
-
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
COMPLETED · Phase 1
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI